Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials

We assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes mellitus based on kidney function via pooled analysis of two 24-week, randomized, double-blind phase III trials. Data from 470 patients were included (enavogliflozin:...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cardiovascular Diabetology 2024-02, Vol.23 (1), p.71-11, Article 71
Hauptverfasser:	Lyu, Young Sang, Hong, Sangmo, Lee, Si Eun, Cho, Bo Young, Park, Cheol-Young
Format:	Artikel
Sprache:	eng
Schlagworte:	Analysis Analysis of covariance Antidiabetics Benzhydryl Compounds - adverse effects Beta cells Blood Glucose Blood pressure Blood sugar Body mass index Care and treatment Clinical trials Dapagliflozin Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes therapy Double-Blind Method Drug administration Enavogliflozin Epidermal growth factor receptors Excretion Glucose Glucosides Glycated Hemoglobin Glycemic control Glycosylated hemoglobin Homeostasis Humans Hypoglycemic Agents - adverse effects Infections Insulin resistance Kidney Kidneys Non-insulin dependent diabetes mellitus Randomized Controlled Trials as Topic Renal function SGLT-2 inhibitor Sodium-Glucose Transporter 2 Inhibitors - adverse effects Statistical analysis Treatment Outcome Type 2 diabetes Urine glucose excretion rate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes mellitus based on kidney function via pooled analysis of two 24-week, randomized, double-blind phase III trials. Data from 470 patients were included (enavogliflozin: 0.3 mg/day, n = 235; dapagliflozin: 10 mg/day, n = 235). The subjects were classified by mildly reduced (60 ≤ eGFR
ISSN:	1475-2840 1475-2840
DOI:	10.1186/s12933-024-02155-9